Albany, NY -- (SBWIRE) -- 07/14/2017 -- Prostate cancer is a cancer of prostate gland, which is a part of male reproductive system. It is the second most common cancer after skin cancer occurring in men. It is prevalent in geriatric men over the age of 50 years. Risk factors for development of prostate cancer are old age, family history, and race. In the U.S., it is more common among the African-American population than Caucasians. Increased prevalence of prostate cancer due to rapidly aging population, growing awareness among people, rising treatment demand, and availability of new treatments are drivers boosting market growth. However, high cost of the treatment, side effects, and prolonged treatment duration are hampering market growth. Unmet medical needs and patent expiry of blockbuster molecules are likely to create lucrative opportunities for new entrants. New product launch and acquisitions are the current market strategies adopted by leading players. For instance, Johnson & Johnson acquired Aragon Pharmaceuticals. Moreover, Astellas Pharma in collaboration with Medivation launched Xtandi in various countries for the treatment of metastatic CRPC.
Read the Comprehensive Overview of Prostate Cancer Treatment Market: http://www.transparencymarketresearch.com/prostate-cancer-treatment-market.html
The global prostate cancer treatment market can be segmented based on type of diagnosis technique, type of cancer, type of therapy, and region. In terms of type of diagnosis technique, the market can be classified into multiparametric MRI (mp-MRI), PSA, rectal exam, and biopsy. Based on type of cancer, the market can be segmented into hormone refractory prostate cancer and hormone sensitive prostate cancer. In terms of type of therapy, the market can be segmented into chemotherapy, hormonal therapy, targeted therapy, immunotherapy, radiation therapy, and surgery. The chemotherapy and hormonal therapy segments dominate the market. Chemotherapy is further classified into apoptosis inducing drugs, angiogenesis inhibitors, and signal transduction inhibitors. Commonly prescribed chemotherapy drugs are docetaxel, etoposide, vinblastine, carboplatin, and vinorelbine. Hormonal therapy is further segmented into anti-androgens (Xtandi, Casodex), luteinizing hormone releasing hormone (LHRH) antagonists (Zytiga, Gonax), and LHRH agonists (Lupron, Zoladex, Eligard, Decapeptyl, Vantas). Radiation therapy can be segmented into external beam radiation therapy which includes 3D conformal radiation therapy, proton beam radiation therapy, and brachytherapy. Types of surgeries performed for treatment of prostate cancer are transurethral resection (TUR), radical prostatectomy, and orchidectomy.
LHRH antagonist Zygita is the gold standard for the treatment of prostate cancer and is witnessing rapid increase in sales. However, loss of exclusivity of Zygita will impact sales during the forecast period. The immunotherapy drugs segment is expected to grow rapidly during the forecast period. Valeant Pharmaceuticals North America LLC's Provenge is a leader in this class. Future molecules in this class are INO-5150 SynCon and PROSTVAC (Bavarian Nordic). Example coming under targeted therapy is Xofigo.
The global prostate cancer treatment market is highly demanding. There are eight plus molecules in phase III of clinical trials and 26 molecules in phase II; of these 21 are small molecules. Major event occurred in forecast period is label extension of Xtandi from treatment of localized prostate cancer to chemotherapy-naïve mCRPC, nmCRPC, and hormone-sensitive prostate cancer. Xtandi's proven safety and efficacy along with ease of administration as compared to Zytiga will make it a market leader during the forecast period.
In terms of region, the global prostate cancer treatment market can be segmented into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. North America and Europe dominate the market. Rising prevalence of disease, world class diagnosis techniques, health awareness among the people, and increasing geriatric population drive the market in these regions. High investment in R&D in the U.S. and presence of African-American population are other factors propelling the market in the U.S.
Asia Pacific is expected to be the fastest growing market during the forecast period. Rising awareness about the disease, government support, and advanced diagnosis are factors boosting the market. Increased investments in research and development of immunotherapy and targeted therapies is creating significant pipeline. This is one of the factors likely to trigger market growth in Asia Pacific.
Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=27005
Key players operating in the global prostate cancer treatment market are Dendreon Corporation, AstraZeneca plc, Johnson & Johnson, Sanofi, Abbott, Astellas Pharma, Inc., Bristol-Myers Squibb, Bayer AG, Ipsen, Tolmar, Inc., Indevus Pharmaceuticals, and Ferring Pharmaceuticals.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.